$ACA

ACA Looks 46.2% Overvalued on GF Value™ Amid CRH Acquisition App

Arcosa Inc (ACA) shareholders approved its acquisition by CRH for $150 per share, pending regulatory approval. ACA's stock is 46.2% overvalued per GF Value™ at $145.45 vs. intrinsic value of $99.52. CRH's acquisition is expected to close in Q1 2027. ACA's GF Score™ is 76/100, with strong momentum and profitability but weak valuation. 9 gurus hold ACA, with 8 adding positions.

Original reporting
Published Sep 5, 2026, 12:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 6, 2026, 4:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$ACA
Neutral
high confidence
Mentioned
$ACA
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ACANeutralLow
01

Why it matters

The acquisition finalizes CRH's expansion in infrastructure, while ACA's stock is already priced near the deal value, limiting immediate trading opportunities.

02

Market read

Primary M&A disclosure for a mid‑cap US stock; modest impact on broader markets.

03

What to watch

Regulatory approval risk and integration costs could affect CRH's long‑term returns.

Relevance 8/10Novelty 8/10Timing: post‑shareholder approval

Background

Arcosa Inc (NYSE: ACA) operates in construction products and announced a cash acquisition by CRH at $150 per share after shareholder approval.

Company-level read

Ticker impact

$ACANeutralHigh confidence
Context

Shareholders approved CRH's all‑cash $150 per share acquisition of Arcosa Inc.

Expected impact

Minor upside if closing premium exceeds market price; otherwise flat.

Evidence & confidence

Acquisition terms were disclosed for the first time; price already reflects premium.

Market effects

Industrial sector may see modest consolidation as CRH adds construction products.

European industrial stocks could benefit from perceived M&A activity.

Limited; primarily affects US‑listed ACA and European‑listed CRH.

Counterpoint

Deal price may be too low if synergies are overestimated; ACA shareholders could push for higher premium.

Key entities

  • Arcosa Inc

    US‑listed industrial firm targeted by the acquisition.

  • CRH plc

    European building materials group acquiring ACA.

Related articles

$ACAHighAI 8/10

Arcosa launches quarterly bondholder calls for senior notes

Arcosa (NYSE: ACA) will start quarterly bondholder calls for its senior notes, beginning with Q2 2026 results. The calls cover $400M 4.375% notes due 2029 and $600M 6.875% notes due 2032. Shareholders approved its $150/share acquisition by CRH (NYSE: CRH), expected to close in Q1 2027.